1 |
Shin, H. J., Baek, K. H., Jeon, A. H., Kim, S. J., Jang, K. L., Sung, Y. C., Kim, C. M. and Lee, C. W. 2003. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 22, 3853-3858.
DOI
|
2 |
Suraweera, A., O'Byrne, K. J. and Richard, D. J. 2018. Combination therapy with Histone Deacetylase Inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi. Front. Oncol. 29, 92.
DOI
|
3 |
Takai, N. and Narahara, H. 2010. Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J. Oncol. 2010, 458431.
|
4 |
Tsuda, H., Yamamoto, K., Inoue, T., Uchiyama, I. and Umesaki, N. 2000. The role of p16-cyclin D/CDK-pRB pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br. J. Cancer 82, 675-682.
DOI
|
5 |
Wang, X., Simpson, E. R. and Brown, K. A. 2015. p53: Protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Res. 75, 5001-5007.
DOI
|
6 |
Wilson, A., Laurenti, E., Oser, G., van der Wath, R. C., Blanco-Bose, W., Jaworski, M., Offner, S., Dunant, C. F., Eshkind, L., Bockamp, E., Lio, P., Macdonald, H. R. and Trumpp, A. 2008. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135, 1118-1129.
DOI
|
7 |
Yoon, S. and Eom, G. H. 2016. HDAC and HDAC inhibitor: From cancer to cardiovascular disease. Chonnam. Med. J. 52, 1-11.
DOI
|
8 |
Yoon, S., Kim, S. Y. and Nam, D. 2016. Improving gene-set enrichment analysis of RNA-seq data with small replicates. PLoS One 11, e0165919.
DOI
|
9 |
Zhou, D., Choi, Y. J. and Kim, J. H. 2017. Histone deacetylase 6 (HDAC6) is an essential factor for oocyte maturation and asymmetric division in mice. Sci. Rep. 7, 8131.
DOI
|
10 |
Aguirre-Ghiso, J. A. 2007. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846.
DOI
|
11 |
Bolden, J. E., Shi, W., Jankowski, K., Kan, C. Y., Cluse, L., Martin, B. P., MacKenzie, K. L., Smyth, G. K. and Johnstone, R. W. 2013. HDAC inhibitors induce tumor-cell- selective pro-apoptotic transcriptional responses. Cell Death Dis. 4, e519.
DOI
|
12 |
Chang, J. C. 2016. Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine (Baltimore) 95, S20-S25.
DOI
|
13 |
Corney, D. C., Flesken-Nikitin, A., Choi, J. and Nikitin, A. Y. Role of p53 and Rb in ovarian cancer. Adv. Exp. Med. Biol. 622, 99-177.
|
14 |
Delcuve, G. P., Khan, D. H. and Davie, J. R. 2012. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin. Epigenetics 4, 5.
DOI
|
15 |
Dong, Z., Yang, Y., Liu, S., Lu, J., Huang, B. and Zhang, Y. 2017. HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer. Oncotarget 9, 512-523.
DOI
|
16 |
Haakenson, J. and Zhang, X. 2013. HDAC6 and ovarian cancer. Int. J. Mol. Sci. 14, 9514-9535.
DOI
|
17 |
Halsall, J. A. and Turner, B. M. 2016. Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success. Bioessays 38, 1102-1110.
DOI
|
18 |
Hervouet, E., Cheray, M., Vallette, F. M. and Cartron, P. F. 2013. DNA methylation and apoptosis resistance in cancer cells. Cells 2, 545-573.
DOI
|
19 |
Lernoux, M., Schnekenburger, M., Dicato, M. and Diederich, M. 2018. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. Pharmacol. Res. 129, 337-356.
DOI
|
20 |
Mottamal, M., Zheng, S., Huang, T. L. and Wang, G. 2015. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20, 3898-3941.
DOI
|
21 |
Phi, L. T. H., Sari, I. N., Yang, Y. G., Lee, S. H., Jun, N., Kim, K. S., Lee, Y. K. and Kwon, H. Y. 2018. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018, 5416923.
|